Posted on 05/19/2009 9:36:36 PM PDT by Coleus
Genetically engineered stem cells from bone marrow showed promise as a potential new way to deliver a cancer-killing protein to tumors, British researchers said on Tuesday. Experiments in cell cultures and in mice showed the adult stem cells a type known as mesenchymal stem cells could home in on cancer cells and deliver a lethal protein that attacked only the cancer while sparing normal healthy tissue.
Weve developed cells which specifically target cancer through the body and deliver an anti-cancer protein to where it is needed in a seek-and-destroy approach, said Dr. Michael Loebinger of University College London, who presented his findings at the American Thoracic Society conference in San Diego. Essentially, weve combined two pieces of research. The first is that mesenchymal stem cells have an innate ability to seek out tumors throughout the body, Loebinger said in a telephone interview.
Loebinger, Dr. S. M. Janes and colleagues altered the cells to express or make the cancer-killing protein called TNF-related apoptosis-inducing ligand or TRAIL. This protein has the ability to cause the death only of cancer cells. By combining these two approaches, we have a cell which has the ability to go around the body and find and destroy tumors, Loebinger said.
Studies in cell cultures showed the cells were able to find and kill cells from lung, squamous, breast and cervical cancer. Lots of cancer have sensitivity to this TRAIL protein, Loebinger said. They also injected the cells into mice with breast tumors and showed they were able to safely kill the tumors but leave healthy tissue intact. When we delivered this therapy, 38 percent of the tumors were completely eliminated.
(Excerpt) Read more at msnbc.msn.com ...
Adult Stem Cells from Fat Tissue Offer Hope for MS Treatment
First-Ever Procedure Uses Patient's Own Adult Stem Cells to Treat Stroke Effects
(Adult) Stem Cells Jumpstart Bone's Healing Process
No borders in this battle against cancer [Adult Stem Cells]
Single factor converts adult stem cells into embryonic-like stem cells
Adult Stem Cells Successfully Reset Immune System for Multiple Sclerosis Patients
Study: (ADULT) Stem Cells Reverse Paralysis in Rats
Adult Stem Cells Already Help Spinal Cord Patients, FDA Embryonic Trials Not Needed
Another medical breakthrough with adult stem cells
To Russia, with hope of a miracle cure (adult stem cells for spinal cord injuries)
No...how dare they? Only the cells of sacrificed human embryos can provide the cures!
Cheers!
They must be itching to put “embryonic” in one of these breakthrough headlines. But it’s conspicuous by its absence.
Notre Dame will supply them for the libs and lots of dead babies too.
thanks, bfl
Wow and double wow!!!!
TRAIL protein looks like an eventual Nobel! Thanks for the ping.
Bookmark
bump
Now THIS is stem cell research that is deserving of support!
bfl
Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer.
It's a lentivirus method of gene therapy. Sixty two percent of the mice had no response or worse, i.e. graft versus host disease or host versus graft disease. Cancer patients are already considered immunocompromised. Any requirement for immunosuppressant drugs would increase morbidity and mortality, IMHO.
bump
Rose Bengal ......Target and destroy the deadliest cancers melanoma, liver & breast while eliminating side effects. Clinical trials for metastatic melanoma and recurrent breast carcinoma are currently underway.
Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative virus hunter method)
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that a poster, Abstract #9060, entitled "Chemoablation of melanoma with intralesional rose bengal (PV-10)", will be presented on June 1, 2009 in the 8:00 a.m. - 12:00 p.m. General Poster Session (Group F, Brd. F15), at the 2009 American Society of Clinical Oncology (ASCO) Scientific Program at the Orange County Convention Center in Orlando, Florida.
Dr. Sanjiv S. Agarwala, Principal Investigator for Provectus' Phase 2 PV-10 trial site at St. Luke's Hospital & Health Network in Bethlehem, PA will present an update on the development efforts with PV-10 for metastatic melanoma, including interim Phase 2 safety and efficacy data on the first 40 subjects in the trial and interim bystander correlation data on response of untreated tumors in subjects whose treated tumors responded successfully. Additional Phase 1 survival data will also be presented.
.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.